The wild type one demonstrated a significant improvement, in comparison to the baseline, of several evaluated parameters assessed at the end of the treatment: FPG, insulinemia, HOMA-IR, ALT, CRP, TBARS (p = 0.0009, 0.006, 0.0001, <0.0001, 0.0005, 0.002, respectively), differently the NAFLD wild type control group showed a statistically significant worsening of TBARS levels at the end of treatment in comparison to baseline (p = 0.001), whereas the mutated one did not show any statistically significant variation of all the clinical, biochemical, and stiffness/CAP assessments (Table 1). The gene discussed is CRP; the disease is metabolic dysfunction-associated steatotic liver disease.